布罗达鲁单抗(抗白介素-17受体A单克隆抗体)治疗中轴型脊柱关节炎:3期研究68周结果
这项在日本、韩国和台湾开展的多中心3期研究中,中轴型脊柱关节炎患者双盲期接受布罗达鲁单抗210 mg皮下注射或安慰剂16周,随后开放扩展至68周。第68周时布罗达鲁单抗组和安慰剂转换组的ASAS 40应答率分别为56.3%和57.4%,ASDAS-CRP均较基线有临床重要改善,安全性特征一致。
要点
- 第68周ASAS 40应答率布罗达鲁单抗组56.3%,安慰剂转换组57.4%。
- 第68周两组ASAS 20应答率相似,分别为71.3%和78.7%。
- ASDAS-CRP较基线变化两组均提示临床重要改善(变化≥1.1)。
核心结论
- 布罗达鲁单抗在中轴型脊柱关节炎患者中68周内显示持续疗效和一致的安全性特征。
研究设计与样本
- 多中心3期研究,在日本、韩国和台湾开展。
- 双盲期16周:布罗达鲁单抗210 mg皮下注射组继续开放扩展52周,安慰剂组于第16周转换为布罗达鲁单抗210 mg。
- 开放扩展期共145例患者接受布罗达鲁单抗(布罗达鲁单抗组n=77,安慰剂组n=68)。
主要发现
- 第68周ASAS 40应答率(95%CI):布罗达鲁单抗组56.3%(44.7%,67.3%),安慰剂组57.4%(44.1%,70.0%)。
- 第68周ASAS 20应答率(95%CI):布罗达鲁单抗组71.3%(60.0%,80.8%),安慰剂组78.7%(66.3%,88.1%)。
- 第68周ASDAS-CRP最小二乘均值变化(95%CI):布罗达鲁单抗组-1.528(-1.737,-1.319),安慰剂组-1.586(-1.815,-1.357),两组均提示临床重要改善(变化≥1.1)。
- 暴露调整事件率(每100患者年):治疗中出现的不良事件(TEAE)为255.9,药物相关TEAE为147.9。
- 最常见TEAE为鼻咽炎(35.6)和上呼吸道感染(14.7)。
关键数值与推荐
- ASAS 40应答率(95%CI):布罗达鲁单抗组56.3%(44.7%,67.3%),安慰剂组57.4%(44.1%,70.0%),第68周。
- ASAS 20应答率(95%CI):布罗达鲁单抗组71.3%(60.0%,80.8%),安慰剂组78.7%(66.3%,88.1%),第68周。
- ASDAS-CRP最小二乘均值变化(95%CI):布罗达鲁单抗组-1.528(-1.737,-1.319),安慰剂组-1.586(-1.815,-1.357),第68周。
- TEAE暴露调整事件率255.9/100患者年,药物相关TEAE 147.9/100患者年。
- 鼻咽炎暴露调整事件率35.6/100患者年,上呼吸道感染14.7/100患者年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the long-term efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis (axSpA). METHODS: Patients receiving subcutaneous brodalumab 210 mg during the 16-week double-blind period of this multicentre, phase 3 study conducted across Japan, Korea and Taiwan continued the same during the 52-week open-label extension, whereas patients receiving placebo switched to brodalumab 210 mg at week 16. Efficacy [Assessment of SpondyloArthritis International Society (ASAS) 40 and ASAS 20 response rates; change from baseline in AS Disease Activity Score using CRP (ASDAS-CRP)] and safety were evaluated. RESULTS: Overall, 145 patients (brodalumab, n = 77; placebo, n = 68) received brodalumab during the open-label extension. ASAS 40 response rates (95% CI) of 56.3% (44.7%, 67.3%) and 57.4% (44.1%, 70.0%) were achieved in the brodalumab and placebo groups, respectively, at week 68. ASAS 20 response rates (95% CI) achieved at week 68 in both treatment groups were similar [brodalumab, 71.3% (60.0%, 80.8%); placebo, 78.7% (66.3%, 88.1%)]. The least squares mean change (95% CI) in ASDAS-CRP at week 68 suggested a clinically important improvement (change, ≥1.1) in both treatment groups [brodalumab, -1.528 (-1.737, -1.319); placebo, -1.586 (-1.815, -1.357)]. The exposure-adjusted event rates (per 100 patient-years) for treatment-emergent adverse events (TEAEs) and drug-related TEAEs were 255.9 and 147.9, respectively; nasopharyngitis (35.6) and upper respiratory tract infection (14.7) were the most common TEAEs. CONCLUSIONS: Brodalumab demonstrated sustained efficacy and a consistent safety profile in patients with axSpA over 68 weeks. STUDY REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02985983.
引用
- Kim TH, Kishimoto M, Wei JC, et al. Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study. Rheumatology (Oxford). 2023. PMID: 36130275. doi:10.1093/rheumatology/keac522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。